MYL
Mylan NV
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Market Cap: 8.42 Billion
Primary Exchange: NASDAQ
Website: http://mylan.co.uk
Shares Outstanding: 542 Million
Float: 538 Million
Dividend: (%)
Beta: 0.757108445873012
Sector: Health Technology
Industry: Pharmaceuticals: Generic
Ethical Flags
Longest drawdown: 1559 trading days
From: 2015-04-24 To: 2020-11-13
Lowest Point:
Healthcare Stocks: Invest In Business, Not Science
via: SeekingAlpha at 2019-06-13 02:35:46:000
By Vinay Thapar Healthcare stocks served as powerful painkillers during last year's market declines. Yet the sector offers much more than just downside protection for investors who focus on business potential and resist the urge to predict scientific breakthroughs. While the MSCI World I… read more...
Teva hits 19-year low on continued pricing pressure
via: SeekingAlpha at 2019-06-12 06:49:59:000
Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|